Johnson & Johnson

Intel

Tariff Reprieve Lifts Stocks; Intel, J&J in Focus

Johnson & Johnson's Cardiovascular Business Drives Medtech Growth in 2025 with 15.8% YoY Sales Increase

强生

Citigroup

Citigroup reiterates Buy rating, raises Johnson & Johnson PT to $250.

Johnson & Johnson: BofA Securities Raises PT to $221, Maintains Neutral Rating

Johnson & Johnson: TD Cowen Maintains Buy, Raises PT to $250

Catalyst<ul> <li>Strong cash reserves relative to market value indicate solid financial positioning for JNJ.</li></ul>Risk<ul> <li>Bearish technical signals such as the MACD Death Cross and Hanging Man indicate potential downward pressure on JNJ.</li> <li>Large and medium-sized fund flows show negative trends, suggesting reduced institutional confidence in JNJ.</li></ul>

Key Factors

Johnson & Johnson reported Q4 2025 sales of $24.6 billion, exceeding estimates, and issued 2026 guidance above forecasts, with expected sales between $99.5 billion and $100.5 billion.Johnson & Johnson's cardiovascular business drove a 15.8% YoY increase in medtech sales to $8.93 billion in 2025, with multiple units exceeding $1 billion in revenue.Citigroup raised its price target for Johnson & Johnson to $250, reiterating a Buy rating, while BofA Securities raised its PT to $221 and maintained a Neutral rating.Johnson & Johnson's stock price was reported as undervalued by 43.6% based on a DCF analysis, which estimated its intrinsic value at $386.56 per share.A federal court ruling allowed expert testimony linking Johnson & Johnson's talc products to cancer, permitting the first federal trial in the ongoing litigation, which J&J has vowed to appeal.

Recent Updates

JNJ News